Publication at First Faculty of Medicine |
2023
Abstract
Early breast cancer is a malignancy with a high chance of complete cure, so it makes sense to exert every effort to eliminate it completely. However, the patient often pays for this with a range of side effects.
The main problem is the persistent uncertainty about the individual presence of minimal residual disease, which is the main reason for adjuvant treatment. Neoadjuvant therapy not only alters the operability of the tumour, but also affects any distant micrometastases.
Thus, it is also indicated for operable but aggressive breast cancer subtypes such as HER2+ or triple negative breast cancer (TNBC). The aim of this review is to answer the question of where current developments in the treatment of early breast cancer are heading.